Phage Display Articles

Articles

  • Discovery of PSMA-Specific Peptide Ligands for Targeted Drug Delivery.

    Prostate-specific membrane antigen (PSMA) has been widely used as a biomarker or targeting receptor for prostate cancer therapy because of its overexpression in most prostate cancer cells. In this study, a novel combinatorial phage biopanning procedure was developed to discover PSMA-specific peptides that can be potentially used as targeting ligands for targeted drug delivery to prostate cancer cells.

    Published September 8, 2016
  • Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release.

    A major challenge of targeted molecular imaging and drug delivery in cancer is establishing a functional combination of ligand-directed cargo with a triggered release system. Here we develop a hydrogel-based nanotechnology platform that integrates tumor targeting, photon-to-heat conversion, and triggered drug delivery within a single nanostructure to enable multimodal imaging and controlled release of therapeutic cargo.

    Published February 9, 2016
  • Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer.

    While there has been extensive development of anti-cancer drugs for treatment of prostate cancer, the therapeutic efficacy of such drugs remains inadequate in many cases. Here, we performed in vitro biopanning of the PC3 human prostate carcinoma cell line to select prostate cancer-specific peptides by phage display.

    Published May 25, 2016